PMID- 36163658
OWN - NLM
STAT- MEDLINE
DCOM- 20220928
LR  - 20221024
IS  - 1815-7920 (Electronic)
IS  - 1027-3719 (Linking)
VI  - 26
IP  - 10
DP  - 2022 Oct 1
TI  - High-dose proton pump inhibitors are associated with hospitalisation in 
      bronchiectasis exacerbation.
PG  - 917-921
LID - 10.5588/ijtld.22.0098 [doi]
AB  - BACKGROUND Bronchiectasis is a common respiratory disease complicated by periodic 
      exacerbations. The association with different degrees of gastric acid suppression 
      has not been well studied.METHODS A retrospective cohort study of 350 patients 
      was conducted to investigate the association of different gastric acid 
      suppressants with bronchiectasis exacerbation that required hospitalisation. 
      Components of FACED (FEV(1)% predicted, age, chronic colonisation by Pseudomonas 
      aeruginosa, radiological extent of the disease, and dyspnoea) were adjusted in 
      multivariate analysis.RESULTS Among patients with exacerbation of bronchiectasis, 
      52 (14.9%) required hospitalisation. Prescription of a high-dose of proton pump 
      inhibitors (PPI) was associated with increased risk of bronchiectasis 
      exacerbation requiring hospitalisation (adjusted OR 2.77, 95% CI 1.01-7.59; P = 
      0.05). There was no significant association with use of a histamine-2 receptor 
      antagonist (H2RA) (OR 1.28, 95% CI 0.32-5.06) or low-dose PPI (OR 1.47, 95% CI 
      0.42-5.13). Nonetheless, patients prescribed a high dose of PPI required a 
      significantly longer hospital stay for exacerbation (13.1 +/- 1.4 days) than 
      patients not prescribed a gastric acid suppressant (8.2 +/- 2.6 days) or those on a 
      low dose PPI (8.3 +/- 1.3 days) and H2RA (6.50 +/- 1.50 days).CONCLUSIONS Risk of 
      bronchiectasis exacerbation requiring hospitalisation was increased among 
      high-dose PPI users, but not those prescribed an H2RA or low-dose PPI.
FAU - Kwok, W C
AU  - Kwok WC
AD  - Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong 
      Kong Special Administrative Region, China.
FAU - Cheung, K S
AU  - Cheung KS
AD  - Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong 
      Kong Special Administrative Region, China, Department of Medicine, Shenzhen 
      Hospital, The University of Hong Kong- Shenzhen, Guangdong, China.
FAU - Ho, J C M
AU  - Ho JCM
AD  - Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong 
      Kong Special Administrative Region, China.
FAU - Li, B
AU  - Li B
AD  - Department of Surgery, Queen Mary Hospital, The University of Hong Kong, Hong 
      Kong Special Administrative Region, China.
FAU - Ma, T F
AU  - Ma TF
AD  - Department of Statistics, University of South Carolina, Columbia, SC, USA.
FAU - Leung, W K
AU  - Leung WK
AD  - Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong 
      Kong Special Administrative Region, China.
LA  - eng
PT  - Journal Article
PL  - France
TA  - Int J Tuberc Lung Dis
JT  - The international journal of tuberculosis and lung disease : the official journal 
      of the International Union against Tuberculosis and Lung Disease
JID - 9706389
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
RN  - 820484N8I3 (Histamine)
SB  - IM
MH  - *Bronchiectasis/drug therapy
MH  - Histamine
MH  - Histamine H2 Antagonists/adverse effects
MH  - Hospitalization
MH  - Humans
MH  - *Proton Pump Inhibitors/adverse effects
MH  - Retrospective Studies
EDAT- 2022/09/28 06:00
MHDA- 2022/10/25 06:00
CRDT- 2022/09/27 00:33
PHST- 2022/09/27 00:33 [entrez]
PHST- 2022/09/28 06:00 [pubmed]
PHST- 2022/10/25 06:00 [medline]
AID - 10.5588/ijtld.22.0098 [doi]
PST - ppublish
SO  - Int J Tuberc Lung Dis. 2022 Oct 1;26(10):917-921. doi: 10.5588/ijtld.22.0098.